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Rexin-G, a nonreplicative pathology-targeted   retroviral 
vector  bearing  a  cytocidal  cyclin  G1  construct,  was 
tested  in  a  phase  I/II  study  for  gemcitabine-resistant 
pancreatic cancer. The patients received escalating doses 
of Rexin-G intravenously from 1 × 1011 colony-forming 
units (cfu) 2–3× a week (dose 0–1) to 2 × 1011 cfu 3× 
a week (dose 2) for 4 weeks. Treatment was continued 
if there was less than or equal to grade 1 toxicity. No 
dose-limiting toxicity (DLT) was observed, and no vec-
tor  DNA  integration,  replication-competent  retrovirus 
(RCR), or vector-neutralizing antibodies were noted. In 
nine evaluable patients, 3/3 patients had stable disease 
(SD) at dose 0–1. At dose 2, 1/6 patients had a partial 
response (PR) and 5/6 patients had SD. Median progres-
sion-free survival (PFS) was 3 months at dose 0–1, and 
>7.65 months at dose 2. Median overall survival (OS) 
was 4.3 months at dose 0–1, and 9.2 months at dose 
2. One-year survival was 0% at dose 0–1 compared to 
28.6% at dose 2, suggesting a dose–response relation-
ship between OS and Rexin-G dosage. Taken together, 
these data indicate that (i) Rexin-G is safe and well toler-
ated, and (ii) Rexin-G may help control tumor growth, 
and may possibly prolong survival in gemcitabine-resis-
tant pancreatic cancer, thus, earning US Food and Drug 
Administration’s (FDA) fast-track designation as second-
line treatment for pancreatic cancer.
Received 24 May 2009; accepted 9 September 2009; published online 
13 October 2009. doi:10.1038/mt.2009.228
IntroductIon
Pancreatic cancer is one of the most lethal of cancers that affects 
~37,000 and kills ~33,000 persons in the United States each year.1,2 
Currently available treatments for pancreatic cancer have minimal 
impact on disease outcome. The median survival time for patients 
with locally advanced pancreatic cancer is 6–10 months, and for 
metastatic pancreatic cancer, this figure drops to 3–6 months.3,4 
Gemcitabine,  a  deoxycytidine  analogue,  has  been  shown  to 
improve the quality of life of patients with advanced pancreatic 
cancer,4,5  although  the  median  survival  was  extended  merely 
5  weeks,  as  compared  to  5-fluorouracil  (median  survival  5.65 
months for gemcitabine versus 4.41 months for 5-fluorouracil).6 
Recently, the molecular-targeted therapies, cetuximab (Erbitux) 
and bevacizumab (Avastin), which target the HER-1/EGF and 
VEGF receptor-mediated pathways, respectively, failed to show 
significant survival benefits in phase III clinical trials for pancreatic 
cancer.7 Further, the tyrosine kinase inhibitor, erlotinib (Tarceva), 
given first-line in combination with gemcitabine, was reported to 
improve survival by only 2 weeks compared to gemcitabine alone: 
median  survival  6.3  months  versus  5.9  months,  respectively.8,9 
Currently, all existing therapies offer meager patient benefits, and 
there is no US Food and Drug Administration (FDA)–approved 
second-line therapy for pancreatic cancer that has failed a gem-
citabine-containing regimen.10 Therefore, innovative therapies are 
urgently needed.
Among the leading alternatives to traditional chemotherapeu-
tics, both cancer gene therapy and cancer immunotherapy strate-
gies are currently under active clinical investigation.11–13 Rexin-G, 
a  nonreplicative-targeted  retroviral  vector,  also  described  as  a 
pathotropic nanoparticle (~100 nm in diameter) bearing a cyto-
cidal dominant negative cyclin G1 construct, represents the first 
and, so far only, targeted gene therapy vector that has been tested 
in the clinic.14 Its “pathotropic” guidance system incorporates a 
physiological surveillance function (a collagen-binding peptide) 
derived from von Willebrand clotting factor, which is respon-
sible  for  guiding  platelets  to  injured  tissues  where  collagen  is 
exposed.15 When injected intravenously, this surveillance func-
tion  guides  the  Rexin-G  nanoparticles  into  cancerous  lesions, 
where collagenous matrix proteins are either exposed via protease 
activity and/or are newly deposited as a result of tumor inva-
sion,  tumor-associated  angiogenesis  and  stroma  formation,16,17 
thus enhancing effective vector concentration within the tumor 
microenvironment. The genetic payload is a dominant negative 
mutant of the human cyclin-G1 gene,18 an essential and early part 
of the cell cycle control pathway.19 Targeting and aborting the early 
regulatory components of the cancer cell’s universal replication 
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mechanism arrests the cell cycle in G1 phase, causing cell death 
via   apoptosis-mediated pathways.
In the United States, Rexin-G is currently being tested simul-
taneously in three phase I/II clinical trials for chemotherapy-re-
sistant metastatic sarcoma, pancreatic cancer, and breast cancer, 
respectively, and in one phase II study for chemotherapy-resistant 
metastatic osteosarcoma. In this article, we report on the results of 
the phase I/II study of Rexin-G for metastatic pancreatic cancer 
that is considered refractory to a gemcitabine-containing regimen 
(standard therapy).
results
Patient population
The current phase I/II study, which incorporates a phase II com-
ponent by adaptive design, enrolled 13 patients at higher doses 
than  a  previous  phase  I  study  conducted  at  the  Mayo  Clinic, 
Rochester, MN,20 with repeated treatment cycles to evaluate the 
efficacy  and  cumulative  toxicity  of  Rexin-G.  Escalating  doses 
starting from 1 × 1011 colony-forming units (cfu) intravenously 
2–3× a week (or 8–12 × 1011 cfu over 4 weeks; dose level 0–1) to 
2 × 1011 cfu 3× a week (or 24 × 1011 cfu over 4 weeks; dose level 2) 
were given. Patients who had grade 1 or less toxicity received addi-
tional treatment cycles. Further, across-the-board dose escalation 
was allowed by the FDA from dose level 0 to dose level 2 as part of 
an adaptive study design, when the safety of Rexin-G was docu-
mented in concurrent clinical studies for sarcoma.21 In the dose 
level 0–1 cohort, the median total cumulative dose received was 
7 × 1011 cfu, and one of six patients received chemotherapy after 
Rexin-G was discontinued. In the dose level 2 cohort, the median 
total cumulative dose was 60 × 1011 cfu (an 8.5-fold higher dose 
than that received at dose level 0–1 cohort). Two of seven patients 
received  chemotherapy  after  Rexin-G  was  discontinued,  and 
one patient received 10 cycles and is continuing treatment with 
Rexin-G with a sustained partial response (PR) for >1 year.
Table  1 shows the demographics of the patient population. 
The  median  age  was  64  years.  There  were  equal  numbers  of 
females and males. There were nine white Caucasians and four 
Asians. All patients had metastatic disease, thus, bearing a poorer 
prognosis than those with locally advanced or regional disease, 
and  had  failed  a  median  of  two  gemcitabine-containing  regi-
mens. All patients had a performance score of 1 (based on Eastern 
Cooperative Oncology Group scoring system; Table 2).
Analysis of safety
Treatment-related adverse events occurred in 2/13 patients and 
are listed in Table  3. Two patients experienced grade 1 fatigue, 
and one patient had grade 1 chills and grade 1 headache. There 
was  no  dose-limiting  toxicity  (DLT)  or  organ-related  toxicity. 
There were no antibodies detected in the patients’ serum samples 
tested. Further, all DNA samples from patients’ peripheral blood 
lymphocytes were found to be negative for replication-competent 
retrovirus (RCR) or vector DNA integration.
Analysis of efficacy
In the first cohort, three patients were taken off study before com-
pletion of one treatment cycle due to disease-related complica-
tions (n = 1) or due to a personal decision to discontinue therapy 
(n = 2). In the second cohort, one patient was taken off study 
before completion of one treatment cycle. Patients who completed 
at least one treatment cycle and who had at least one follow-up 
positron emission tomography–computed tomography (PET-CT) 
scan were considered evaluable.
Table 4 gives the tumor responses using response evaluation 
criteria in solid tumors (RECIST), International PET and CHOI 
criteria for each dose level. Among the nine evaluable patients, 
three of three patients had stable disease (SD) at dose level 0–1, 
whereas one of six patients had a PR and five of six patients had 
SD at dose level 2 by RECIST. Further, the median progression-
free survival (PFS) time at dose level 0–1 was 3 months, and 
median overall survival (OS) time was 4.3 months (2.6 months 
for all six patients at dose level 0–1). In contrast, the median PFS 
time at dose level 2 was ≥7.65 months and median OS time was 
9.2 months (9.3 months for all seven patients at dose level 2). 
table 1  demographics of the patient population (N = 13)
Age (years)
  Median 64 (Range 50–83)
Gender
  Female 7 (54%)
  Male 6 (46%)
Race
  White 9 (69%)
  Black —
  Hispanic —
  Asian 4 (31%)
  Others —
Disease stage
  Metastatic 13 (100%)
  Nonmetastatic —
Performance score
 0 —
 1 13 (100%)
No. of previous gemcitabine-containing regimens
Median 2 (range: 1–3)
table 2  ecoG performance scoring system
description score
Fully active, able to carry on all predisease performance without 
restriction
0
Restricted in physically strenuous activity but ambulatory and 
able to carry out work of a light or sedentary nature, e.g., light 
housework, office work
1
Ambulatory and capable of all self-care but unable to carry out 
any work activities. Up and about >50% of waking hours
2
Capable of only limited self-care, confined to bed or chair >50% 
of waking hours
3
Completely disabled. Cannot carry on any self-care. Totally 
confined to bed or chair
4
Abbreviation: ECOG, Eastern Cooperative Oncology Group.Molecular Therapy  vol. 18 no. 2 feb. 2010  437
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The Kaplan–Meier analysis of OS in the “intent-to-treat” groups 
are shown in Figure 1.
Correlative  analysis  showed  that  FDG  uptake  was  signifi-
cantly reduced (>25%) in one of three patients at dose level 0–1 
and in one of six patients at dose level 2 with the rest having SD 
in both cohorts (Table  4). Similarly, tumor density was signifi-
cantly reduced (>15%) in 1/3 patients at dose level 0–1 and in 2/6 
patients at dose level 2. These corroborative data indicate that the 
International PET and CHOI criteria may be sensitive indicators 
of early tumor response to Rexin-G therapy in pancreatic cancer.
Correlative analysis of changes in CA19.9 level with response 
and tumor progression by PET-CT scan showed various patterns 
in three patients who completed at least three treatment cycles 
of Rexin-G: (i) an early fall in CA19.9 level after the first treat-
ment cycle in a patient with SD for 6 months, followed by a rise in 
CA19.9 level simultaneous with disease progression by CT, (ii) an 
initial rise in CA19.9 level followed by a delayed fall after two treat-
ment cycles (12-week follow-up) in one patient with sustained SD, 
and (iii) a gradual rise in CA19.9 level to moderately high levels 
over 13 months in a patient with sustained PR by CT.
Table 5 shows the percent of patients surviving 6 months and 
12 months according to dose level. At dose level 0–1, only 17% 
of patients survived ≥6 months and none survived 12 months. In 
contrast, at dose level 2, 57% of patients survived ≥6 months and 
28.6% survived ≥12 months.
One  patient  underwent  a  biopsy  of  a  tumor  nodule  after 
three treatment cycles of Rexin-G. Tissue sections of the biopsied 
tumor showed that the predominant cell population in the resid-
ual tumor nodule consisted of host mononuclear cells express-
ing CD45+ leukocyte common antigen (Figure 2c) and a small 
proportion (15%) of CK17+ pancreatic cancer cells (Figure 2a, 
boxed).  Immunocytochemical  phenotyping  of  the  tumor-infil-
trating lymphocytes revealed a complete cadre of T and B cells 
as  well  as  antigen-presenting  cells  including  CD35+  dendritic 
cells (Figure 2d), CD20+ B cells (Figure 2e), CD4+ helper T cells 
(Figure 2f), and CD8+ killer T cells (Figure 2g) surrounding the 
cancer cells and focal apoptotic nuclei, and significant stroma for-
mation and/or reparative fibrosis (seen as intense blue-staining 
material by trichrome staining for stromal collagen; Figure 2b). 
These  findings  are  consistent  with  those  observed  in  preclini-
cal and clinical studies with Rexin-G treatment.16,17,22–25 The pre-
ponderance of tumor-infiltrating lymphocytes (CD35+ dendritic 
cells, CD20+ B cells, CD4+ helper T cells, and CD8+ killer T cells) 
table 3  treatment-related adverse events (by nIH ctcAe version 3)
dose level (n) Adverse event
no. of patients with  
grade 1 toxicity
no. of patients with  
grade 2 toxicity outcome
1 (6) None — — —
2 (7) Fatigue 2a — One resolved
Chills 1 — Resolved
Headache 1 — Resolved
Abbreviation: NIH, National Institutes of Health.
aUnresolved fatigue was later attributed to progressive disease in one patient.
table 4  the impact of rexin-G treatment on tumor response, progression-free survival, and overall survival in patients with pancreatic cancer 
refractory to gemcitabine (treated analysis)
dose level (number of 
patients)
tumor response  
by recIst
tumor response  
by Pet
tumor response  
by cHoI
Median PFs by  
recIst (months)
Median overall  
survival (months)
0–1 (3) 1 × 1011 cfu  
BIW-TIW
3 SD 1 PR, 2 SD 1 PR, 2 SD 3 4.3a
2 (6) 2 × 1011 cfu TIW 1 PR, 5 SD 1 PR, 5 SD 2 PR, 4 SD ≥7.65 9.2a
Abbreviations: BIW, two times a week; cfu, colony-forming units; PET, positron emission tomography; PFS, progression-free survival; PR, partial response; RECIST, 
response evaluation criteria in solid tumors; SD, stable disease; TIW, three times a week.
aThirteen patients were started on Rexin-G, four of whom had <1 treatment cycle or did not return for evaluation; median overall survival was 2.6 months for six 
patients at dose level 0–1 and 9.3 months for seven patients at dose level 2.
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Figure 1  Kaplan–Meier analysis for the two cohorts of patients with 
gemcitabine-resistant  pancreatic  cancer  (intent-to-treat  analysis) 
showing the relationship between overall survival (os) and rexin-G 
dosage.
table 5  the impact of rexin-G dosage on overall survival in patients 
with pancreatic cancer refractory to gemcitabine (intent-to-treat 
analysis)
dose level
number of 
patients
% surviving 
6 months
% surviving 
12 months
0–1 1 × 1011 cfu BIW-TIW 6 17 0
2 2 × 1011 cfu TIW 7 57 28.6
Abbreviation: cfu, colony-forming unit.438  www.moleculartherapy.org  vol. 18 no. 2 feb. 2010     
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within the tumor nodule affirm the potential of using pathotropic 
  nanoparticles bearing cytokine genes (e.g., GM-CSF) for in situ 
cancer vaccination strategies.26
dIscussIon
Rexin-G is the first targeted genetic medicine to gain orphan drug 
designation for pancreatic cancer in the United States (http://www.
fda.gov/orphan/index.htm). There are no alternative therapies for 
chemotherapy-resistant  pancreatic  cancer  that  impact  survival. 
Therefore, attempts to develop salvage therapy for this rapidly fatal 
disease could be considered a futile effort. However, the results 
of pioneering studies conducted in the Philippines,24,27 in Japan 
(T. Imamura, Chiba Port Medical Clinic, personal communication, 
April 2008), and now, in the United States, indicate that Rexin-G 
would have clinical utility as a   second-line treatment for pancreatic 
cancer. The promising results of this phase I/II study suggest clini-
cal benefits of Rexin-G (given as second to fourth-line treatment) 
that approach those reported in a phase III study wherein gem-
citabine and erlotinib were given as first-line treatment.8,9 In that 
phase III study, the median survival was 5.9 months with gemcit-
abine given first-line, and 6.3 months with gemcitabine + erlotinib 
(but with increased toxicity), whereas the median survival with 
Rexin-G given as second- to fourth-line treatment is 9.2 months 
with no organ-related toxicity. Therefore, it would be appropriate 
to expedite the development of this potentially safe and effective 
drug as a treatment for pancreatic cancer.28
Using higher doses than those used in an early phase I safety 
study at the Mayo Clinic,20 we report improved tumor responses 
[PR or SD, and no progression of disease (PD)] using all avail-
able  measures  including  RECIST,  International  PET  criteria 
and CHOI criteria, and extended PFS (median ≥7.65 months) 
and OS (median 9.2 months) at dose level 2 compared to those 
reported in the Mayo Clinic study (median PFS of 32 days and 
median OS of 3.5 months).20 In the current phase I/II study, a 
dose–  response   relationship between OS and Rexin-G dosage is 
apparent (Figure 1). This is consistent with the results of a simul-
taneous phase I/II study in sarcoma wherein the dose–response 
relationship between OS time and Rexin-G dosage was statistically 
  significant (P < 0.005) (ref. 21). Taken together, these data confirm 
the results of previous preclinical and clinical studies conducted 
in the Philippines that demonstrated that Rexin-G has antitumor 
activity as a single therapeutic agent in pancreatic cancer.24,27
In  summary,  we  report  that  the  primary  objective  of  this 
phase I/II study has been met, that is, the safety of Rexin-G has 
been demonstrated. There was no DLT or organ-related toxic-
ity with repeated infusions of Rexin-G given intravenously at the 
specified doses. The first of the two secondary objectives has also 
been met. The results of these studies show no evidence of vec-
tor specific or neutralizing antibodies in the sera of patients even 
after seven treatment cycles, indicating the low immunogenicity 
of Rexin-G. In contrast, the frequent development of antibodies 
directed against targeted monoclonal antibodies used as treat-
ment for many types of cancers have precluded their subsequent 
use. There was no evidence of any vector DNA integration or 
recombination  (RCR)  events  in  nontarget  organs  (peripheral 
blood lymphocytes), thereby confirming the exceptional safety 
record of Rexin-G.
Finally, the second of the secondary objectives has also been 
met with SD achieved after one treatment cycle of Rexin-G at all 
dose levels used. Improved tumor responses (one PR and five SDs) 
as well as longer PFS and OS were achieved in the dose level 2 
cohort.
Taken together, the clinical data suggest that (i) Rexin-G is safe 
and well tolerated, (ii) Rexin-G may help control tumor growth, 
and  (iii)  Rexin-G  may  improve  survival  in  patients  with  che-
motherapy-resistant metastatic pancreatic cancer. In June 2009, 
Figure 2  Immunohistochemical characterization of tumor-infiltrating lymphocytes in tumor. (a) Hematoxylin and eosin stain of tumor   nodule 
with CK17+ cancer cells (boxed), (b) trichrome stain for collagen (blue staining material), (c) cells expressing the leukocyte common antigen (  reddish 
brown staining material), (d) CD35+ dendritic cells, (e) CD20+ B cells, (f) CD4+ helper T cells, (g) CD8+ killer T cells (reddish brown staining material). 
ECM, extracellular matrix; fib, fibrosis; im, immune cells; tu, tumor.Molecular Therapy  vol. 18 no. 2 feb. 2010  439
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the FDA granted Rexin-G fast-track designation as second-line 
  treatment of pancreatic cancer, based on the recognized potential 
of Rexin-G to address this unmet medical need. Therefore, a phase 
II/III pivotal two-arm randomized study is planned to confirm the 
OS benefit of Rexin-G as monotherapy versus physician’s choice 
of therapy in gemcitabine-refractory pancreatic cancer. Overall 
response rates, PFS, CA19.9 levels, quality of life measures, and 
histopathology of surgically excised tumors will be further corre-
lated with Rexin-G treatment in a larger number of patients.
MAterIAls And MetHods
Study design. The study employed a modification of the standard cohort 
of three design.29 Three patients were treated at each dose level with expan-
sion to six patients per cohort if DLT was observed in any one of the three 
first patients at each dose level. Maximum tolerated dose was defined as 
the highest safely tolerated dose, where ≤1 patient experienced DLT, with 
the next higher dose level having at least two patients who experienced 
DLT. DLT was defined as any grade 3, 4, or 5 adverse event considered 
possibly, probably, or definitely related to the study drug, excluding grade 3 
absolute neutrophil count lasting <72 hours, grade 3 alopecia, or any grade 
3 or worse nausea, vomiting, or diarrhea where the patient did not receive 
maximal supportive care.29 Each cohort of three was also expanded to six 
or seven patients if significant biologic activity was noted.
Adaptive trial design. A phase II efficacy component was incorporated 
in the phase I/II study by allowing additional treatment cycles to be 
given if the patient had less than or equal to grade 1 toxicity. Further, 
across the board, dose escalations were allowed up to dose level 2 for 
patients with less than or equal to grade 1 toxicity when safety at the 
specified dose level was documented. The principal investigator was also 
allowed to recommend surgical resection/debulking, and Rexin-G was 
continued if residual disease was found by histological examination or 
PET-CT scan.
Clinical objectives/end points. The primary objective of this study is to 
determine the clinical toxicity of escalating doses of Rexin-G as defined 
by patient performance status, toxicity assessment score, and hematologic 
and metabolic profiles. Secondary objectives include (i) evaluation of the 
potential of Rexin-G for evoking an immune response, recombination 
events and/or unwanted vector integration in nontarget organs, and (ii) 
identification of an antitumor response to Rexin-G.
Patient population. The present phase I/II trial enrolled 13 patients with 
a  pathologic  diagnosis  of  pancreatic  adenocarcinoma  that  was  locally 
advanced  or  metastatic  that  had  failed  gemcitabine  or  a  gemcitabine-
  containing  regimen.  Histologic  or  cytologic  confirmation  at  diagnosis 
or  recurrence  was  required.  Inclusion  criteria  consisted  of  an  Eastern 
Cooperative Oncology Group performance score of 0–1 and adequate 
hematologic,  hepatic,  and  kidney  function.  Exclusion  criteria  included 
human immunodeficiency virus, hepatitis B virus, or hepatitis C virus 
positivity,  clinically  significant  ascites,  medical  or  psychiatric  condi-
tions that could compromise successful adherence to the protocol, and 
unwillingness to employ effective contraception during treatment with 
Rexin-G and for 6 weeks following treatment completion. An amend-
ment to the New Investigational Drug application was approved by the 
FDA (BB-IND#11586) in July 2007, and the clinical protocol (C07-105) 
was reviewed and approved by the Western Institutional Review Board, 
Olympia, WA.
Patient recruitment and assignment. The phase I/II clinical trial using 
Rexin-G for pancreatic cancer was registered on http://www.clinicaltri-
als.gov (NCT00504998) within 1 week of study initiation, and patients 
were recruited on a first-come first-serve basis after appropriate screening 
procedures were conducted. Written informed consent was obtained from 
each patient at the time of enrollment. This is an open label study using 
escalating doses of Rexin-G. Six patients were enrolled at dose level 0–1 
followed by a dose escalation in six patients at dose level 2 when safety/
toxicity data in at least three patients at dose level 1 had been recorded, 
and no DLT was encountered. One patient was included in the dose level 2 
cohort because he received an intrapatient dose escalation from dose level 
0 to dose level 2.
Treatment. Rexin-G is a nonreplicative “pathotropic” or disease-seeking 
nanoparticle bearing a functional collagen-binding motif on its enve-
lope protein18 and encoding an N-terminal deletion mutant construct of 
human cyclin G1 (ref. 18) under the control of a hybrid Moloney murine 
leukemia virus long-terminal repeat promoter. The gene expression vec-
tor also contains the neomycin phosphotransferase gene driven by the 
SV40 early promoter, which was used for precise vector titer assays. The 
Rexin-G vector is produced by transient co-transfection of three separate 
plasmids in 293T cells (human kidney 293 cells transformed with the SV40 
large T antigen) maintained as a fully validated master cell bank.21,24,27 The 
final product exhibits a vector titer of 5 × 109 cfu/ml, a biologic potency of 
50–70% growth inhibitory activity in target cancer cells, <550 base-pair 
residual DNA, no detectable E1A or SV40 large T antigen, and no detect-
able RCR.30 The clinical vector is stored in volumes of 23 ml in 30 ml vials 
or 40 ml in 150 ml cryobags at −80 °C. Preparation of the Rexin-G vector 
for patient administration consisted of rapid thawing of the vector in the 
vial in a 34 °C water bath. The vector was thawed 15–30 minutes prior 
to infusion into the patient, and given intravenously over 5–10 minutes. 
All personnel who handled and disposed of the vector observed Biosafety 
Level 2 compliance in accordance with the National Institutes of Health 
Guidelines for Research Involving Recombinant DNA molecules.
Thirteen  patients  were  treated  with  escalating  doses  of  Rexin-G. 
Briefly, each treatment cycle was 6 weeks, consisting of 4 weeks treatment 
and 2 weeks rest period. The following two dose levels were employed: 
dose level 0 = 1 × 1011 cfu two times a week for 4 weeks (dose per 4-week 
cycle: 8 × 1011 cfu); dose level 1 = 1 × 1011 cfu three times a week for 4 
weeks (dose per 4-week cycle: 12 × 1011 cfu); dose level 2 = 2 × 1011 cfu 
three times a week for 4 weeks (dose per 4-week cycle: 24 × 1011 cfu). 
Treatment  was  continued  if  there  was  less  than  or  equal  to  grade  1 
toxicity.
Safety and efficacy evaluation. Pretreatment evaluation included his-
tory, physical exam, complete blood count with differential and plate-
let count, a serum chemistry panel including aspartate transaminase, 
alanine transaminase, alkaline phosphatase, creatinine, and total bili-
rubin, assessment of coagulation status including prothrombin time, 
international normalized ratio, and activated partial thromboplastin 
time, testing for human immunodeficiency virus, hepatitis B virus, and 
hepatitis C virus, imaging evaluation to include a whole body FDG/
PET-CT scan, electrocardiography, and chest X-ray. All patients had 
a complete blood count and serum chemistry panel performed weekly 
during treatment.
Safety analysis. Toxicity was assessed before each vector infusion, and 
before beginning an additional treatment cycle. Toxicity was graded using 
NCI CT-CAE version 3 (ref. 31). Patients had serum collected for vector-
specific antibody detection and peripheral blood mononuclear cells col-
lected for assessment of vector DNA integration and RCR at the end of 
4 weeks, at 6 weeks, or before the start of a treatment cycle.
Vector-related studies were performed in the Epeius Biotechnologies 
Quality  Control  Unit,  San  Marino,  CA  using  standard  operating 
procedures in compliance with good laboratory practices. Detection of 
antivector antibodies in serum, testing for presence of RCR and vector 
DNA integration studies in patient’s peripheral blood lymphocytes, were 
performed as previously described.20,21440  www.moleculartherapy.org  vol. 18 no. 2 feb. 2010     
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Efficacy  analysis.  Efficacy  assessment  with  FDG  PET-CT  scan  was 
  performed at the end of 4 weeks, at the end of 6 weeks, or before starting 
an additional treatment cycle up to 12 weeks, and every 12 weeks there-
after. All PET-CT images were performed and reviewed by independent 
radiologists of the Medical Imaging Center of Southern California, Santa 
Monica, CA, who are experts at nuclear and PET imaging, and who were 
blinded to the Rexin-G dose levels. Tumor responses [complete response 
(CR); PR; or SD] were evaluated using the NCI RECIST criteria.32
Correlative analysis. Tumor responses were also assessed using modifica-
tions of the International PET criteria33 and the CHOI criteria.34 The mod-
ified International PET Criteria defines a CR as disappearance of FDG 
avid uptake in target and nontarget lesions with no new lesions; PR as a 
decrease in maximum standard uptake value of >25% from baseline with 
no new lesions and no obvious progression of nontarget lesions; SD as not 
meeting the criteria for CR, PR, or PD, and no symptomatic deterioration 
attributed to tumor progression; and PD as an increase in maximum stan-
dard uptake value of >25% from baseline, any new lesions, and obvious 
progression of nontarget lesions.
The modified CHOI criteria defines CR as the disappearance of all 
disease and no new lesions; PR as a decrease in size of ≥10% or a decrease 
in CT density (Hounsfeld units) ≥15% with no new lesions and no obvious 
progression of nonmeasurable disease; SD as not meeting the criteria for 
CR, PR, or PD, and no symptomatic deterioration attributed to tumor 
progression; and PD as an increase in unidimensional tumor size of >10% 
and did not meet criteria for PR by CT density, any new lesions, including 
new tumor nodules in a previously cystic tumor.
Overall evaluation of toxicity/tumor responses was conducted by the 
principal  investigator  and  associate,  Sarcoma  Oncology  Center,  Santa 
Monica, CA (S.P.C. and V.S.C., respectively).
Statistical  analysis.  Frequency  tables,  graphs,  and  summary  statistics 
were used to describe patient characteristics and outcome data. Follow-up 
data from October 2007 to 13 January 2009 were analyzed. Kaplan–Meier 
methodology35 was used to describe graphically the distribution of OS. OS 
time was calculated in days and divided by 30.4 to convert to months. PFS 
time was approximated, using the times of patient evaluations. OS and PFS 
times were compared in groups of patients treated at different dose levels, 
using permutation tests on the logrank statistic with at least 10,000 replica-
tions. Tumor-response data by different specific criteria (RECIST, PET, and 
CHOI criteria) were reported. Reported P values are two-sided, and P < 
0.05 was considered statistically significant. Analysis was done using NCSS 
software (Number Cruncher Statistical Systems, Kaysville, UT). Statistical 
analysis was performed by a biostatistician not otherwise involved in the 
study (W.C.B.). 
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